KILITCH DRUGS (INDIA) LTD. - 524500 - Closure of Trading Window
The trading window for dealing in securities of the Company will remain closed for designated person of the Company and their immediate relative with effect from Saturday, 1st July, 2023 till expiry of 48 hours after declaration of financial results of the Company for the quarter ended 30th June, 2023 KILITCH DRUGS (INDIA) LTD. - 524500 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Pursuant to Regulation 39(3) of SEBI (Listing Obligations and Disclosure Requirement) Regulations, 2015, we hereby inform you that the Company has received intimation in relation with loss of Share Certificate as attached from the Registrar and Share Transfer Agents of the Company i.e. Link Intime India Private Limited. KILITCH DRUGS (INDIA) LTD. - 524500 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Pursuant to Regulation 39(3) of SEBI (Listing Obligations and Disclosure Requirement) Regulations, 2015, we hereby inform you that the Company has received request from the Registrar and Share Transfer Agents of the Company i.e. Link Intime India Private Limited for issue of duplicate share certificate KILITCH DRUGS (INDIA) LTD. - 524500 - Q4 FY 23 Earnings Call Transcript
Please find enclosed herewith a copy of the transcript of the Company's Q4 FY23 earnings conference call dated 2nd June, 2023. KILITCH DRUGS (INDIA) LTD. - 524500 - Submission Of Answer To The Unanswered Questions During The Conference Call Dated 2Nd June, 2023
In continuation of our letter dated 2nd June, 2023 regarding submission of recording of conference call dated 2nd June, 2023, please find enclosed herewith the answer to the questions remained unanswered during the said conference call. The transcript of the same will be submitted shortly. KILITCH DRUGS (INDIA) LTD. - 524500 - Recording Of Conference Call
Pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, further to our intimation dated 29th May, 2023 regarding earnings call, the audio recording of the call held today i.e. Friday, 2nd June, 2023 is available on our website. The same can be accessed through below link: https://kilitch.com/wp-content/uploads/2023/06/Kilitch-Drugs-India-Limited-Q4-FY23-Concall-Audio.mp3 KILITCH DRUGS (INDIA) LTD. - 524500 - Corrigendum To The Outcome Of The Board Meeting Dated 29Th May, 2023
This has a reference to the outcome of board meeting dated 29th May, 2023 wherein the Board considered and approved the Audited Financial Results (Standalone and Consolidated) for the quarter and year ended 31st March, 2023. Post submission of the said outcome to the stock exchanges, an inadvertent error was notice in the amount in consolidated statement of Cash Flow under the head 'Capital expenditure on PPE, CWIP including capital advances' was not captured properly due to link issue. The revised Consolidated Audited Financial Results for the quarter and year ended 31st March, 2023 is attached herewith. All other particulars and details remain unchanged. The corrigendum shall be read with the Outcome of Board meeting dated 29th May, 2023. KILITCH DRUGS (INDIA) LTD. - 524500 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Please find enclosed herewith our Press Release relating to financial results for the fourth quarter ended 31st March, 2023, which we shall be releasing after sending this letter to you. KILITCH DRUGS (INDIA) LTD. - 524500 - Announcement under Regulation 30 (LODR)-Newspaper Publication
Please find enclosed the copies of the newspaper publication pertaining to the extract of the financial results of the Company for the quarter and year ended 31st March, 2023. The said extract of the financial results was published on Marathi and English edition on 30th May, 2023.
